Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery

Anesthesia and Analgesia

Volumn 101, Issue 2, 2005, Pages 325-327

  Price, Susanna ^a   Pepper, John R ^a   Jaggar, Siân I ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CRITICAL ILLNESS; DISEASE SEVERITY; FEMALE; HEART DISEASE; HEART SURGERY; HUMAN; JEHOVAH'S WITNESS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SALVAGE THERAPY;

EID: 22944448326     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000159158.70532.D0     Document Type: Article

References (17)

1. Cross MH. Autotransfusion in cardiac surgery. Perfusion 2001; 16:391-400.
2. Yazicioglu L, Eryilmaz S, Sirlak M, et al. Recombinant human erythropoietin administration in cardiac surgery. J Thorac Cardiovasc Surg 2001;122:741-5.
3. Atabek U, Alvarez R, Pello MJ, et al. Erythropoietin accelerates hematocrit recovery in post-surgical anemia. Am Surg 1995;61: 74-7.
4. Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 2000; 18:161-71.
5. Hardy JF. Pharmacological strategies for blood conservation in cardiac surgery: Erythropoietin and antifibrinolytics. Can J Anaesth 2001;48:S24-31.
6. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: A systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Transfus Med 1998;8:309-17.
7. Cordon PJ, Stafford-Smith M, White WD, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 1999; 14:1158-62.
8. von Ahsen N, Muller C, Serke S, et al. Important role of non-diagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27:2630-9.
9. Eckardt K. Anaemia of critical illness: Implications for understanding and treating rHuEPO resistance Nephro Dial Transplant 2002;17:48-55.
10. Santoro A. Anemia in renal insufficiency. Rev Clin Exp Hematol. 2002;Suppl 1:12-20.
11. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001;59:246-51.
12. Elliot JM, Virankabutra T, Jones S, et al. Erythropoietin mimics the acute phase response in critical illness. Crit Care 2003;7: R35-40.
13. Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med 2003;31:S651-7.
14. Major A, Mathez-Loic F, Rohling R, et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 1997;98:292-4.
15. Danielson B. R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant. 1995;10 Suppl 2:69-73.
16. Flaharty KK, Caro J, Earsley A, et al. Pharmacokinetics and erythropoietin response to human recombinant erythropoietin in healthy men. Clin Parmacol Ther 1990;47:557-64.
17. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002;288:2827-35.